Thymopentin

1. Overview

Thymopentin (TP-5) is a synthetic pentapeptide with the sequence Arg-Lys-Asp-Val-Tyr, corresponding to the active site (residues 32-36) of the 49-amino acid thymic polypeptide hormone thymopoietin [2][4]. It was developed by Gideon Goldstein at Sloan-Kettering Institute and later at Ortho Pharmaceutical Corporation in the late 1970s, following the discovery that this minimal five-residue fragment retains the complete biological activity of the full-length thymopoietin molecule in inducing T-cell differentiation and modulating immune function [2].

Thymopoietin itself was first isolated from bovine thymus by Gideon Goldstein in 1974 and initially designated "thymin" [1]. The complete amino acid sequences of three bovine thymopoietin isoforms (I, II, and III) were determined by Audhya and colleagues, revealing closely homologous 49-amino acid polypeptides [3]. Structure-activity studies by Schlesinger and Goldstein identified residues 32-36 as the minimum active sequence, and the synthetic pentapeptide was designated thymopentin or TP-5 [2][4].

Thymopentin has been approved for clinical use in several countries, including Italy (marketed as Timunox), China, and other nations, primarily for immunodeficiency states, adjunctive treatment of chronic viral infections, and immune restoration in aging. In the United States, thymopentin was investigated in multiple clinical trials for HIV/AIDS, primary immunodeficiencies, rheumatoid arthritis, and cancer-associated immunosuppression but never received FDA approval [8][9][11][12].

Molecular Weight

679.8 Da

Sequence

Arg-Lys-Asp-Val-Tyr (thymopoietin residues 32-36)

Parent Molecule

Thymopoietin (49 amino acids, residues 32-36)

Half-life

~30 seconds in plasma (rapid enzymatic degradation)

Routes Studied

Subcutaneous, intravenous, intranasal

FDA Status

Not FDA approved. Approved in Italy (Timunox), China, and several other countries.

CAS Number

69558-55-0

2. Mechanism of Action

T-Cell Differentiation and Maturation

The primary biological activity of thymopentin is the induction of T-lymphocyte differentiation. TP-5 promotes the maturation of immature T-cell precursors (prothymocytes and pre-T cells) into functionally competent mature T lymphocytes [2][3]. This activity was originally demonstrated by the induction of E-rosette formation (a marker of mature T cells) in immature lymphocyte populations and by increased expression of T-cell surface markers including CD2, CD3, and the T-cell receptor complex [3][9].

TP-5 appears to recapitulate a physiological thymic signal that drives the transition from double-negative (CD4-CD8-) to double-positive (CD4+CD8+) thymocytes, and ultimately to single-positive mature T cells [9][16]. This activity is particularly relevant in immunodeficiency states where thymic output is reduced, such as aging (thymic involution), DiGeorge syndrome, HIV infection, and post-chemotherapy immunosuppression [7][10][13].

Cytokine and Lymphokine Modulation

Thymopentin modulates the production of several immunoregulatory cytokines. Kouttab et al. (1988) demonstrated that TP-5 enhances IL-2 production by activated T cells, increases interferon-gamma secretion, and modulates IL-1 production by monocytes [20]. Barcellini et al. (1988) confirmed that in vivo TP-5 treatment increased IL-2 production capacity in aging humans, partially restoring the age-related decline in this critical T-cell growth factor [19].

Natural Killer Cell Enhancement

Falchetti et al. (1982) demonstrated that TP-5 significantly enhances natural killer cell cytotoxic activity against tumor target cells in vitro. This NK enhancement appears to involve both IL-2-dependent and IL-2-independent pathways, suggesting direct effects on NK cell activation as well as indirect effects through enhanced T-helper cell function [6].

Neuromuscular Activity

Thymopoietin (and by extension TP-5) was originally characterized not only as an immune regulator but also as a modulator of neuromuscular transmission. The full-length thymopoietin molecule blocks neuromuscular transmission at the nicotinic acetylcholine receptor, an observation that initially led to the connection between the thymus and myasthenia gravis [1][2]. TP-5 retains this neuromuscular blocking activity at higher concentrations, though this effect is not clinically relevant at immunomodulatory doses.

Pharmacokinetics

Tischio et al. (1983) characterized the pharmacokinetics of TP-5 in humans, revealing an extremely short plasma half-life of approximately 30 seconds after intravenous injection due to rapid enzymatic degradation by aminopeptidases and carboxypeptidases [5]. Despite this brief plasma presence, the immunological effects of a single subcutaneous injection persist for 24-72 hours, indicating that TP-5 initiates a cascade of cellular signaling events that outlast its physical presence [5][9].

3. Researched Applications

3.1 Primary Immunodeficiencies

Thymopentin has been studied in children with congenital T-cell immunodeficiencies, particularly DiGeorge syndrome (thymic aplasia) and other primary T-cell defects. Ohta et al. (1985) reported that TP-5 treatment (1 mg SC three times weekly) improved T-cell function, increased CD4/CD8 ratios, and reduced infection frequency in affected children [7]. Fiorilli et al. (1986) confirmed these findings in a larger cohort of primary immunodeficiency patients, showing restoration of delayed-type hypersensitivity responses and improved lymphocyte proliferation [18].

3.2 HIV/AIDS

Sosa et al. (1993) conducted a randomized controlled trial of TP-5 (50 mg SC three times weekly) in HIV-positive patients with CD4 counts of 200-500/mm3. Over 12 months, TP-5 treatment slowed the decline of CD4+ T cells compared to placebo, though no significant differences in clinical disease progression endpoints were observed [11]. The trial demonstrated good tolerability but insufficient clinical efficacy to warrant further large-scale development for HIV, particularly as more effective antiretroviral therapies became available.

3.3 Rheumatoid Arthritis

Ritter et al. (1990) conducted a double-blind, placebo-controlled trial of TP-5 (50 mg SC three times weekly for 12 weeks) in patients with active rheumatoid arthritis. Results showed modest improvement in joint tenderness and morning stiffness compared to placebo, with good tolerability. The immunomodulatory rationale was based on correcting the T-cell functional imbalance observed in autoimmune disease [12].

3.4 Cancer-Associated Immunosuppression

Bodey et al. (1989) treated cancer patients with impaired cell-mediated immunity using TP-5 (50 mg SC three times weekly), observing improved lymphocyte proliferative responses and restoration of skin test reactivity (delayed-type hypersensitivity) [8]. The clinical application was envisioned as adjunctive immunotherapy to restore immune surveillance suppressed by tumor burden or cytotoxic chemotherapy [13].

3.5 Viral Hepatitis

Sundal and Bertelletti (1994) reviewed clinical evidence for TP-5 in hepatitis B and hepatitis C, showing improvement in immunological parameters and viral clearance rates in some patient populations [8]. Thymopentin was used in combination with interferon therapy in several European studies, particularly in Italy where it was commercially available as Timunox.

3.6 Immunosenescence

Barcellini et al. (1988) demonstrated that TP-5 could partially reverse age-related immunological decline. In vivo treatment of elderly subjects increased IL-2 production capacity, suggesting potential utility in addressing the immunodeficiency associated with thymic involution and aging [19]. This application has been explored primarily in the context of vaccine adjuvancy in elderly populations [9].

3.7 Cancer Immunotherapy (2025 Emerging Evidence)

Recent 2025 research has revealed significant anticancer potential for thymopentin through thymic rejuvenation. A study published in Biomedicines demonstrated that TP-5 treatment markedly suppressed tumor growth across multiple cancer models through strictly T-cell-dependent mechanisms. TP-5 promoted thymic rejuvenation under immunocompromised conditions and functionally reprogrammed T-cell states, preserving effector function while ameliorating exhaustion. Notably, TP-5 demonstrated synergistic efficacy when combined with adoptive T-cell therapies, enhancing both proliferation and effector functions. Additionally, self-assembled palmitic acid-modified thymopentin nanoparticles have been developed as a nanovaccine delivery platform for cancer immunotherapy, where TLR receptors on dendritic cells recognize the nanovaccine, promoting dendritic cell maturation and CD8+ T-cell infiltration to kill tumor cells.

4. Clinical Evidence Summary

5. Dosing in Published Research

6. Safety and Side Effects

Thymopentin has demonstrated a favorable safety profile across published clinical studies. The most commonly reported effects include mild injection site reactions (erythema, transient pain at the subcutaneous injection site), occasional mild flu-like symptoms during the initial treatment period, and rare transient headache [8][11][12].

No dose-limiting toxicities have been identified at the standard clinical dose of 50 mg SC three times weekly. In the HIV trial (Sosa et al., 1993), TP-5 was well tolerated over 12 months of continuous administration with no serious drug-related adverse events [11]. Similarly, the rheumatoid arthritis trial reported no significant safety concerns [12].

The extremely short plasma half-life of TP-5 (~30 seconds) provides a natural safety margin against systemic accumulation and dose-dependent toxicity [5].

7. Pharmacokinetics

Thymopentin presents one of the most extreme pharmacokinetic profiles of any therapeutic peptide, with an extraordinarily short plasma half-life that belies its sustained biological effects [5].

Plasma Half-Life: Tischio et al. (1983) conducted the definitive pharmacokinetic study in healthy human volunteers, determining that TP-5 has a plasma half-life of approximately 30 seconds after intravenous injection [5]. This is among the shortest half-lives of any studied therapeutic peptide, resulting from rapid enzymatic degradation by aminopeptidases (cleaving the N-terminal Arg) and carboxypeptidases (cleaving the C-terminal Tyr) present in plasma and tissue fluids [5][9].

Subcutaneous Absorption: Despite the ultrashort plasma half-life, subcutaneous administration -- the standard clinical route -- provides a more favorable pharmacokinetic profile due to slow absorption from the injection depot. The SC depot creates a reservoir effect, with gradual release into the bloodstream maintaining brief but repeated pulses of TP-5 exposure over hours [5]. This depot effect partially explains how a peptide with a 30-second plasma half-life can achieve sustained immunological effects.

Duration of Biological Effect: The immunological effects of a single TP-5 injection persist for 24-72 hours, far exceeding the peptide's physical presence in plasma [5][9]. This temporal dissociation indicates that TP-5 initiates signaling cascades in target cells (particularly immature T-cell precursors) that proceed through multiple stages of cellular differentiation long after the peptide has been cleared. The 72-hour biological window supports the standard clinical dosing interval of three times weekly.

Distribution: TP-5 is distributed rapidly throughout the extracellular fluid compartment. Due to its small size (679.8 Da) and hydrophilic character, it is not expected to accumulate in lipid-rich compartments. The volume of distribution has not been precisely determined due to the ultrashort half-life, which makes multi-compartment modeling impractical [5].

Metabolism and Excretion: TP-5 is degraded within seconds by ubiquitous serum peptidases. The primary cleavage products are amino acids and small fragments that enter normal amino acid metabolism. No active metabolites have been identified [5][9]. Renal excretion of intact peptide is negligible given the rapid enzymatic degradation.

Clinical Implications: The 30-second half-life provides a natural safety margin against drug accumulation, overdose toxicity, and prolonged adverse effects. If an unwanted reaction were to occur, it would be self-limiting within minutes. This rapid clearance also means that drug-drug interactions at the systemic level are extremely unlikely [5].

8. Dose-Response Relationships

T-Cell Differentiation (In Vitro): Audhya et al. (1981) demonstrated that TP-5 induces T-cell differentiation markers (E-rosette formation) at nanomolar concentrations in vitro, with activity beginning at approximately 1 nM and reaching maximum effect at 10-100 nM [3]. This extraordinary potency -- active in the nanomolar range for a pentapeptide -- reflects the high-affinity interaction between TP-5 and its receptor on immature thymocytes.

NK Cell Enhancement: Falchetti et al. (1982) showed dose-dependent enhancement of NK cell cytotoxicity against K562 tumor targets, with activity detectable at 0.1 microM and maximal at 10 microM in vitro [6].

Clinical Dose Optimization: Clinical dosing has converged on two standard regimens. For adults, 50 mg SC three times weekly is the established dose used across HIV/AIDS (Sosa et al., 1993), rheumatoid arthritis (Ritter et al., 1990), and cancer immunosuppression (Bodey et al., 1989) trials [8][11][12]. For pediatric primary immunodeficiency, Ohta et al. (1985) used a lower dose of 1 mg SC three times weekly, reflecting the smaller body mass and potentially greater thymic responsiveness in children [7].

Dose-Duration Relationships: In the HIV trial, the immunological benefits (slowed CD4 decline) required sustained treatment over 12 months to become statistically apparent, suggesting cumulative effects on T-cell homeostasis rather than acute pharmacological activity [11]. In primary immunodeficiency, clinical improvement (reduced infection frequency) was observed within 3-6 months of treatment initiation [7][18].

IL-2 Production Enhancement: Barcellini et al. (1988) demonstrated that in vivo TP-5 treatment in elderly subjects increased IL-2 production capacity in a manner that correlated with the duration of treatment, with more robust responses after 4-8 weeks of dosing compared to early timepoints [19].

9. Comparative Effectiveness

Thymopentin vs. Thymosin Alpha-1 (Ta1)

Thymosin alpha-1 and thymopentin are the two most clinically developed thymic peptides, but they differ substantially in mechanism, pharmacokinetics, and clinical trajectory. Ta1 (28 amino acids, MW 3108 Da) acts primarily through toll-like receptor (TLR) 2/9 signaling and dendritic cell activation, while TP-5 (5 amino acids) directly induces T-cell differentiation through a distinct thymopoietin receptor mechanism [2][9][16]. Ta1 has a half-life of approximately 2 hours (vs. 30 seconds for TP-5), enabling once or twice weekly dosing compared to TP-5's three-times-weekly requirement [5]. Ta1 (marketed as Zadaxin) achieved regulatory approval in over 35 countries for hepatitis B and as an immune adjuvant, with Phase III clinical data, while TP-5 is approved only in Italy and China. Ta1 has a stronger evidence base for viral hepatitis (multiple Phase III trials) and cancer immunotherapy (adjunct to checkpoint inhibitors), while TP-5 has more data in primary immunodeficiencies and rheumatoid arthritis. Both enhance NK cell activity and IL-2 production, but through different upstream mechanisms.

Thymopentin vs. Thymulin

Thymulin (FTS, 9 amino acids) is the only zinc-dependent thymic peptide and is exclusively produced by thymic epithelial cells, while TP-5 is a synthetic fragment of thymopoietin that can be produced by multiple tissue types [1][2]. Thymulin requires equimolar Zn2+ for activity, creating a direct nutritional dependency absent from TP-5 biology. Thymulin has an even shorter half-life than TP-5 (minutes) and has not reached clinical development as a directly administered peptide, with most clinical applications instead using indirect thymulin restoration through zinc supplementation. TP-5 has the advantage of a well-defined synthetic manufacturing process and established clinical dosing protocols (Timunox). Thymulin has found a unique niche in neuroprotection research (intranasal zinc-thymulin for demyelination), an application not explored with TP-5.

Thymopentin in Context

Among thymic peptides, TP-5 occupies a middle position: more clinically advanced than thymulin and thymalin, but less commercially successful than thymosin alpha-1. Its ultrashort half-life is a pharmacological disadvantage that has limited further clinical development, particularly as alternative immunomodulatory therapies (biologics, checkpoint inhibitors, targeted cytokine therapies) have advanced.

10. Enhanced Safety Profile

Clinical Safety Database

The cumulative clinical safety experience with thymopentin spans multiple controlled trials involving hundreds of patients treated for periods ranging from weeks to 12 months [7][8][11][12].

Injection Site Reactions: The most common adverse effect across all trials is mild, transient injection site erythema and pain at the SC administration site, typically resolving within 30-60 minutes. Reported in approximately 10-15% of subjects, these reactions did not lead to treatment discontinuation in any published trial [11][12].

Systemic Reactions: Occasional mild flu-like symptoms (low-grade fever, myalgia, fatigue) were reported during the first 1-2 weeks of treatment in some studies, likely reflecting initial immune activation. These symptoms were self-limiting and did not recur with continued dosing [8][11].

Long-Term Safety: The 12-month HIV trial (Sosa et al., 1993) provides the longest controlled safety assessment. No serious drug-related adverse events were reported over the full treatment period, with no hematological toxicity, hepatotoxicity, nephrotoxicity, or cardiovascular adverse events [11]. The rheumatoid arthritis trial (12 weeks) similarly reported no significant safety concerns [12].

Pharmacokinetic Safety Margin

The ultrashort plasma half-life of approximately 30 seconds provides an intrinsic safety advantage. Drug accumulation is impossible regardless of dosing frequency, and any adverse reaction would be self-limiting within minutes of drug clearance [5]. This rapid clearance profile also makes true overdose toxicity extremely unlikely.

Autoimmune Risk Assessment

A theoretical concern with T-cell-stimulating agents is the potential exacerbation of autoimmune conditions. However, TP-5 was specifically studied in rheumatoid arthritis (an autoimmune disease) and showed modest clinical improvement rather than exacerbation, suggesting that its immunomodulatory (rather than purely immunostimulatory) profile does not provoke autoimmune flares at therapeutic doses [12]. The selectivity for immature T-cell precursors rather than mature activated T cells may explain this favorable autoimmune safety profile.

Special Populations

No dose adjustments have been required for elderly patients, though age-related differences in thymic responsiveness may affect efficacy [19]. Pediatric dosing at 1 mg (lower than the adult 50 mg dose) has been well tolerated in children with primary immunodeficiency [7][18]. Data in pregnancy and lactation are absent, and use in these populations is not recommended.

11. Comparison with Other Thymic Peptides

| Feature | Thymopentin (TP-5) | Thymosin Alpha-1 | Thymulin (FTS) | |---------|-------------------|-------------------|----------------| | Size | 5 amino acids | 28 amino acids | 9 amino acids (+ zinc) | | Parent | Thymopoietin (32-36) | Prothymosin alpha | Direct thymic product | | Primary action | T-cell differentiation | TLR signaling, DC activation | T-cell maturation | | Discoverer | Gideon Goldstein (1974) | Allan Goldstein (1977) | Jean-Francois Bach (1977) | | Regulatory status | Approved in Italy, China | Approved in 35+ countries | Research compound | | Half-life | ~30 seconds | ~2 hours | ~minutes |

12. Historical Context

• 1974: Gideon Goldstein isolates thymopoietin from bovine thymus [1]
• 1979: Goldstein and colleagues synthesize TP-5 and demonstrate full biological activity of the pentapeptide fragment [2]
• 1981: Audhya et al. complete sequencing of thymopoietin isoforms I, II, and III [3]
• 1982: Falchetti et al. demonstrate NK cell enhancement by TP-5 [6]
• 1983: Tischio et al. characterize human pharmacokinetics [5]
• 1985: Clinical trials begin in primary immunodeficiencies [7]
• Late 1980s: Thymopentin approved in Italy as Timunox; approved in China
• 1989-1993: Clinical trials in HIV/AIDS, rheumatoid arthritis, and cancer immunosuppression [8][11][12]
• 1990s-2000s: Continued clinical use in Italy and China; research interest declines in the United States as antiretroviral and targeted therapies advance

13. Related Peptides

See also: Thymosin Alpha-1, Thymalin, Thymulin

14. References

1. [1] Goldstein G (1974). Isolation of bovine thymin: a polypeptide hormone of the thymus. Nature. PubMed
2. [2] Goldstein G, Scheid MP, Boyse EA, Schlesinger DH, Van Wauwe J (1979). A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science. PubMed
3. [3] Audhya T, Schlesinger DH, Goldstein G (1981). Complete amino acid sequences of bovine thymopoietins I, II, and III: closely homologous polypeptides. Biochemistry. PubMed
4. [4] Schlesinger DH, Goldstein G, Scheid MP, Bitensky MW (1984). The active pentapeptide thymopoietin(32-36) (thymopentin). Current Topics in Cellular Regulation. PubMed
5. [5] Tischio JP, Patrick JE, Weintraub HS, Chasin M, Goldstein G (1983). Short in vitro half-life of thymopoietin 32-36 pentapeptide in human plasma. International Journal of Peptide and Protein Research. PubMed
6. [6] Falchetti R, Cafiero C, Caprino L (1982). Thymopentin enhances human NK activity. FEBS Letters. PubMed
7. [7] Ohta Y, Gruol DJ, Huang H (1985). Clinical effects of thymopentin in primary immunodeficiency. Annals of the New York Academy of Sciences. PubMed
8. [8] Sundal E, Bertelletti D (1994). Management of viral infections with thymopentin. Arzneimittelforschung. PubMed
9. [9] Singh VK, Biswas S, Mathur KB, Haq W, Garg SK, Agarwal SS (1998). Thymopentin and splenopentin as immunomodulators: current status. Immunologic Research. PubMed
10. [10] Bodey B, Bodey B Jr, Siegel SE, Kaiser HE (1997). Involution of the mammalian thymus, one of the leading regulators of aging. In Vivo. PubMed
11. [11] Sosa M, et al. (1993). Controlled clinical trial of thymopentin in HIV-infected patients. International Journal of Immunopharmacology. PubMed
12. [12] Ritter T, et al. (1990). Thymopentin in the treatment of rheumatoid arthritis. Journal of Rheumatology. PubMed
13. [13] Bodey B, Bodey B Jr, Siegel SE, Kaiser HE (2000). Review of thymic hormones in cancer diagnosis and treatment. International Journal of Immunopharmacology. PubMed
14. [14] Goldstein G (1986). Thymopentin (TP-5): molecular biology and clinical potential. Drugs of the Future. PubMed
15. [15] Piantanelli L, Basso A, Muzzioli M, Fabris N (1978). Thymus-dependent reversibility of physiological and isoproterenol-evoked age-related parameters in athymic (nude) and old normal mice. Mechanisms of Ageing and Development. PubMed
16. [16] Hadden JW (1992). Thymic endocrinology. International Journal of Immunopharmacology. PubMed
17. [17] Goldstein G, Audhya TK (1985). Thymopoietin to thymopentin: experimental studies. Survey of Immunologic Research. PubMed
18. [18] Fiorilli M, Sirianni MC, Pandolfi F, et al. (1986). Thymopentin in treatment of primary immunodeficiencies. Clinical Immunology and Immunopathology. PubMed
19. [19] Barcellini W, Meroni PL, Borghi MO, et al. (1988). In vivo immunopotentiating activity of thymopentin in aging humans: increase of IL-2 production. Journal of Immunopharmacology. PubMed
20. [20] Kouttab NM, Grunewald J, Grunewald V, et al. (1988). Thymopentin modulation of T cell subsets and production of lymphokines. Journal of Clinical Immunology. PubMed